SH2D2A | OmnibusX

Name	Number of supported studies	Average coverage
natural killer cell	32 studies	37% ± 14%	Explore
CD8-positive, alpha-beta T cell	24 studies	28% ± 10%	Explore
mature NK T cell	19 studies	31% ± 11%	Explore
regulatory T cell	16 studies	32% ± 12%	Explore
T cell	14 studies	23% ± 5%	Explore
CD16-positive, CD56-dim natural killer cell, human	14 studies	41% ± 12%	Explore
CD16-negative, CD56-bright natural killer cell, human	13 studies	34% ± 15%	Explore
gamma-delta T cell	13 studies	33% ± 9%	Explore
CD8-positive, alpha-beta memory T cell	12 studies	27% ± 5%	Explore
mucosal invariant T cell	12 studies	32% ± 8%	Explore
CD4-positive, alpha-beta T cell	12 studies	27% ± 9%	Explore
effector memory CD8-positive, alpha-beta T cell	7 studies	29% ± 10%	Explore
effector CD8-positive, alpha-beta T cell	6 studies	32% ± 12%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	5 studies	28% ± 5%	Explore
exhausted T cell	4 studies	41% ± 7%	Explore
effector CD4-positive, alpha-beta T cell	4 studies	35% ± 9%	Explore
effector memory CD4-positive, alpha-beta T cell	4 studies	27% ± 15%	Explore
T-helper 17 cell	4 studies	29% ± 10%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	4 studies	26% ± 8%	Explore
CD4-positive, alpha-beta memory T cell	4 studies	34% ± 13%	Explore
innate lymphoid cell	3 studies	29% ± 9%	Explore

Name	Number of supported studies	Average coverage
peripheral blood	4 studies	18% ± 2%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
lung	100%	535.49	576 / 578	98%	10.97	1131 / 1155
intestine	98%	260.60	945 / 966	99%	11.38	524 / 527
stomach	97%	152.50	349 / 359	99%	12.15	283 / 286
uterus	94%	174.71	160 / 170	95%	13.85	436 / 459
bladder	76%	111.95	16 / 21	97%	11.90	489 / 504
esophagus	73%	79.29	1055 / 1445	98%	11.57	180 / 183
breast	85%	148.81	392 / 459	76%	6.26	849 / 1118
ovary	63%	65.68	113 / 180	97%	9.31	415 / 430
kidney	83%	162.87	74 / 89	68%	5.66	609 / 901
pancreas	55%	46.29	179 / 328	94%	9.26	168 / 178
prostate	98%	272.76	239 / 245	48%	2.00	242 / 502
thymus	95%	190.84	620 / 653	48%	8.39	293 / 605
liver	87%	114.27	196 / 226	52%	3.32	212 / 406
adrenal gland	70%	78.55	181 / 258	63%	12.43	144 / 230
skin	28%	20.17	506 / 1809	93%	11.96	437 / 472
lymph node	0%	0	0 / 0	100%	49.43	29 / 29
spleen	100%	1122.96	241 / 241	0%	0	0 / 0
tonsil	0%	0	0 / 0	100%	16.33	45 / 45
ureter	0%	0	0 / 0	100%	2.61	1 / 1
peripheral blood	100%	2697.58	926 / 929	0%	0	0 / 0
adipose	92%	238.66	1112 / 1204	0%	0	0 / 0
heart	87%	142.76	746 / 861	0%	0	0 / 0
eye	0%	0	0 / 0	61%	3.04	49 / 80
blood vessel	49%	66.86	653 / 1335	0%	0	0 / 0
brain	27%	21.15	701 / 2642	13%	0.82	95 / 705
muscle	18%	11.71	143 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0

Gene name	SH2D2A
Protein name	SH2 domain containing adapter protein 2 transcript variant 3 SH2 domain-containing protein 2A (SH2 domain-containing adapter protein) (T cell-specific adapter protein) (TSAd) (VEGF receptor-associated protein) SH2 domain containing adapter protein 2 transcript variant 4
Synonyms	VRAP SCAP TSAD
Description	FUNCTION: Could be a T-cell-specific adapter protein involved in the control of T-cell activation. May play a role in the CD4-p56-LCK-dependent signal transduction pathway. Could also play an important role in normal and pathological angiogenesis. Could be an adapter protein that facilitates and regulates interaction of KDR with effector proteins important to endothelial cell survival and proliferation.
Accessions	Q9NP31 Q5UBZ2 ENST00000368198.7 [Q9NP31-4] ENST00000392306.2 [Q9NP31-2] Q5UBZ3 ENST00000368199.8 [Q9NP31-1]

SH2D2A report